News
GLUE
5.42
-0.55%
-0.03
Weekly Report: what happened at GLUE last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at GLUE last week (0408-0412)?
Weekly Report · 04/15 09:07
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
NASDAQ · 04/10 12:50
Monte Rosa Therapeutics (GLUE) Gets a Buy from Piper Sandler
TipRanks · 04/09 11:06
Weekly Report: what happened at GLUE last week (0401-0405)?
Weekly Report · 04/08 09:08
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
NASDAQ · 04/04 13:55
Weekly Report: what happened at GLUE last week (0325-0329)?
Weekly Report · 04/01 09:08
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Westport Fuel Systems Inc. (NASDAQ:WPRT) posts wider-than-expected fourth-quarter loss. Krispy Kreme, Inc. And McDonald's expanded their partnership. Stoke Therapeutics, Inc., shares gained 72.6% to $11.24. C3is Inc. Reported a year-over-year increase in financial results.
Benzinga · 03/26 17:45
12 Health Care Stocks Moving In Tuesday's Intraday Session
Stoke Therapeutics (NASDAQ:STOK) stock moved upwards by 71.8% to $11.16 during Tuesday's regular session. The company's, Q4 earnings came out 3 days ago. Mesoblast and OpGen shares also moved upwards.
Benzinga · 03/26 17:31
Weekly Report: what happened at GLUE last week (0318-0322)?
Weekly Report · 03/25 09:07
Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth
Monte Rosa Therapeutics didn't record any revenue over the last year. The company has a negative free cash flow of US$63m and is burning through its cash. Its cash burn relative to its market value is not a concern for the company. It has a long cash runway of 3.7 years and is expected to grow in the next few years. Monte Rosa therapeutics has three warning signs for investors.
Simply Wall St · 03/20 11:04
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
NASDAQ · 03/19 13:55
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
TipRanks · 03/19 12:11
5 Stocks that Analysts Love in March 2024
TipRanks · 03/18 12:35
Weekly Report: what happened at GLUE last week (0311-0315)?
Weekly Report · 03/18 09:08
Wells Fargo Gives a Buy Rating to Monte Rosa Therapeutics (GLUE)
TipRanks · 03/15 09:17
Promising Clinical Progress and Strategic Milestones Bolster Buy Rating for Monte Rosa Therapeutics
TipRanks · 03/14 20:45
GLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023
Monte Rosa Therapeutics reported earnings per share of -58 cents. This was below the analyst estimate for EPS of -33 cents. The company did not report any revenue for the quarter. The stock was down 2.7% to $3.05 in afternoon trading.
Investorplace · 03/14 17:53
Monte Rosa Therapeutics GAAP EPS of -$0.58
Seeking Alpha · 03/14 15:48
Monte Rosa Therapeutics: Q4 Earnings Insights
Monte Rosa Therapeutics reported its Q4 earnings on March 14. The company missed estimates by -76.0%. The company's revenue was down $0 from the same period last year. Monte RosaTherapeutics is expected to announce its earnings on April 14.
Benzinga · 03/14 13:05
More
Webull provides a variety of real-time GLUE stock news. You can receive the latest news about Monte Rosa Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About GLUE
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.